Jaguar Animal Health Appoints Dr. Philippe Brianceau as Chief Veterinary Officer
SAN FRANCISCO–(BUSINESS WIRE)–Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an
animal health company focused on developing and commercializing
first-in-class gastrointestinal products for companion and production
animals, and horses, announced today the appointment of Philippe
Brianceau, DVM, as chief veterinary officer, effective immediately.
Philippe Brianceau brings more than 20 years of animal health experience
following the completion of his doctorate in veterinary medicine from
the Toulouse Veterinary School in France. Most recently, Brianceau
served as director of global pharmaceutical project development at Merck
Animal Health, where he led new product development teams for both
companion and livestock animals. He also served as director of US
clinical research for Merck Animal Health for four years, during which
time he oversaw field study operations and clinical development plans
for new animal drugs. Brianceau began his career in the pharmaceutical
industry in 2001 with Schering Plough Animal Health, followed by
Intervet, where he remained through the organization’s acquisition by
Merck Pharmaceuticals in 2009.
“The addition of Dr. Brianceau to the Jaguar management team comes at a
pivotal time for the Company, as we recently announced additional
positive findings from our SB-300 proof-of-concept study for equine
gastric ulcer syndrome,” said Lisa Conte, Jaguar’s president and CEO.
“Philippe’s research and development experience at Merck Animal Health
in conjunction with his past experience in equine internal medicine and
surgery will provide unparalleled insight into the equine and companion
animal markets—two of our core focus areas. We are confident in his
ability to lead our veterinary team as we pursue regulatory approvals
and initiate further clinical trials and research activities.”
Philippe Brianceau stated, “I am very excited to be named chief
veterinary officer of an emerging animal health company committed to
developing innovative, first-in-class products for both companion and
production animals. I look forward to leveraging my experience in
pharmaceutical product development and my background in veterinary
medicine and surgery to help Jaguar bring the multiple products in its
pipeline to market.”
About Jaguar Animal Health, Inc.
Jaguar Animal Health, Inc. is an animal health company focused on
developing and commercializing first-in-class gastrointestinal products
for companion and production animals. Canalevia™ is Jaguar’s
lead prescription drug product candidate, intended for the treatment of
various forms of diarrhea in dogs. SB-300 is Jaguar’s prescription drug
product candidate for the treatment of gastrointestinal ulcers in
horses. Canalevia™ and SB-300 contain ingredients isolated
and purified from the Croton lechleri tree, which is sustainably
harvested. Neonorm™ Calf and Neonorm™ Foal are the
Company’s lead non-prescription products. Neonorm™ is a
standardized botanical extract derived from the Croton lechleri
tree. Canalevia™ and Neonorm™ are distinct
products that act at the same last step in a physiological pathway
generally present in mammals. Jaguar has nine active investigational new
animal drug applications, or INADs, filed with the FDA and intends to
develop species-specific formulations of Neonorm™ in six
additional target species, formulations of SB-300 in horses, and
Canalevia™ for cats and dogs.
For more information, please visit www.jaguaranimalhealth.com.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking
statements.” These include statements regarding the Company’s intention
to bring the multiple products in its pipeline to market, Jaguar’s plans
to develop species-specific formulations of Neonorm™ in
additional target species, and the Company’s plan to develop
formulations of SB-300 in horses and formulations of Canalevia™
for cats and dogs. In some cases, you can identify forward-looking
statements by terms such as “may,” “will,” “should,” “expect,” “plan,”
“aim,” “anticipate,” “could,” “intend,” “target,” “project,”
“contemplate,” “believe,” “estimate,” “predict,” “potential” or
“continue” or the negative of these terms or other similar expressions.
The forward-looking statements in this release are only predictions.
Jaguar has based these forward-looking statements largely on its current
expectations and projections about future events. These forward-looking
statements speak only as of the date of this release and are subject to
a number of risks, uncertainties and assumptions, some of which cannot
be predicted or quantified and some of which are beyond Jaguar’s
control. Except as required by applicable law, Jaguar does not plan to
publicly update or revise any forward-looking statements contained
herein, whether as a result of any new information, future events,
changed circumstances or otherwise.
Jaguar-JAGX
Contacts
KCSA Strategic Communications
Garth Russell, 212-896-1250
grussell@kcsa.com
or
Allison
Soss, 212-896-1267
asoss@kcsa.com
